clinical trial · NCT03881488
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Locally Advanced Solid TumorMetastatic CancerNon-small Cell Lung CancerSmall Cell Lung CancerMesotheliomaMelanomaHead and Neck CancerCTX-471Pembrolizumab (KEYTRUDA®)
brief summary
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
started
May 17, 2019
primary completion
May 21, 2025
completion
May 21, 2025
last updated
Apr 17, 2026
official title
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol